180 related articles for article (PubMed ID: 38504063)
21. Effectiveness and Safety of Anticoagulation Therapy in Frail Patients With Atrial Fibrillation.
Kim D; Yang PS; Sung JH; Jang E; Yu HT; Kim TH; Uhm JS; Kim JY; Pak HN; Lee MH; Lip GYH; Joung B
Stroke; 2022 Jun; 53(6):1873-1882. PubMed ID: 35109686
[TBL] [Abstract][Full Text] [Related]
22. Improved risk stratification of patients with atrial fibrillation: an integrated GARFIELD-AF tool for the prediction of mortality, stroke and bleed in patients with and without anticoagulation.
Fox KAA; Lucas JE; Pieper KS; Bassand JP; Camm AJ; Fitzmaurice DA; Goldhaber SZ; Goto S; Haas S; Hacke W; Kayani G; Oto A; Mantovani LG; Misselwitz F; Piccini JP; Turpie AGG; Verheugt FWA; Kakkar AK;
BMJ Open; 2017 Dec; 7(12):e017157. PubMed ID: 29273652
[TBL] [Abstract][Full Text] [Related]
23. Use of Oral Anticoagulation in a Real-World Population With Device Detected Atrial Fibrillation.
Kaplan RM; Ziegler PD; Koehler J; Landman S; Sarkar S; Passman RS
J Am Heart Assoc; 2020 Dec; 9(24):e018378. PubMed ID: 33252286
[TBL] [Abstract][Full Text] [Related]
24. Net benefit of oral anticoagulants in patients with atrial fibrillation and active cancer: a nationwide cohort study.
Atterman A; Friberg L; Asplund K; Engdahl J
Europace; 2020 Jan; 22(1):58-65. PubMed ID: 31750897
[TBL] [Abstract][Full Text] [Related]
25. Thromboembolism and bleeding in patients with atrial fibrillation and liver disease - A nationwide register-based cohort study: Thromboembolism and bleeding in liver disease.
Steensig K; Pareek M; Krarup AL; Sogaard P; Maeng M; Tayal B; Lee CJ; Torp-Pedersen C; Lip GY; Holland-Fischer P; Kragholm KH
Clin Res Hepatol Gastroenterol; 2022 Oct; 46(8):101952. PubMed ID: 35609823
[TBL] [Abstract][Full Text] [Related]
26. Association of CHA
Pundi K; Perino AC; Fan J; Din N; Szummer K; Heidenreich P; Turakhia MP
Am Heart J; 2023 Jul; 261():85-94. PubMed ID: 37024025
[TBL] [Abstract][Full Text] [Related]
27. Oral Anticoagulation and the Risk of Stroke or Death in Patients With Atrial Fibrillation and One Additional Stroke Risk Factor: The Loire Valley Atrial Fibrillation Project.
Fauchier L; Lecoq C; Clementy N; Bernard A; Angoulvant D; Ivanes F; Babuty D; Lip GY
Chest; 2016 Apr; 149(4):960-8. PubMed ID: 26425935
[TBL] [Abstract][Full Text] [Related]
28. Practice Gap in Atrial Fibrillation Oral Anticoagulation Prescribing at Emergency Department Home Discharge.
Kea B; Waites BT; Lin A; Raitt M; Vinson DR; Ari N; Welle L; Sill A; Button D; Sun BC
West J Emerg Med; 2020 Jun; 21(4):924-934. PubMed ID: 32726266
[TBL] [Abstract][Full Text] [Related]
29. Stroke and bleeding risk in atrial fibrillation with CHA2DS2-VASC risk score of one: the Norwegian AFNOR study.
Anjum M; Ariansen I; Hjellvik V; Selmer R; Kjerpeseth LJ; Skovlund E; Myrstad M; Ellekjær H; Christophersen IE; Tveit A; Berge T
Eur Heart J; 2024 Jan; 45(1):57-66. PubMed ID: 37995254
[TBL] [Abstract][Full Text] [Related]
30. CHA
Kim TH; Yang PS; Kim D; Yu HT; Uhm JS; Kim JY; Pak HN; Lee MH; Joung B; Lip GYH
Stroke; 2017 Nov; 48(11):2984-2990. PubMed ID: 28939672
[TBL] [Abstract][Full Text] [Related]
31. Bidirectional effects of oral anticoagulants on gut microbiota in patients with atrial fibrillation.
Li W; Li C; Ren C; Zhou S; Cheng H; Chen Y; Han X; Zhong Y; Zhou L; Xie D; Liu H; Xie J
Front Cell Infect Microbiol; 2023; 13():1038472. PubMed ID: 37033478
[TBL] [Abstract][Full Text] [Related]
32. Stroke Risk Stratification Schemes in Atrial Fibrillation in the Era of Non- Vitamin K Anticoagulants: Misleading and Obsolete, At Least for the "Low-Risk" Patients?
Manolis AS; Manolis TA; Manolis AA; Melita H
Curr Drug Targets; 2017 Nov; 18(16):1852-1865. PubMed ID: 27593686
[TBL] [Abstract][Full Text] [Related]
33. Geographic variation in clinical outcomes and anticoagulation among medicare beneficiaries with non-valvular atrial fibrillation.
Atwater BD; Di Fusco M; Keshishian A; Delinger R; Ferri M; Jiang J; Seigel L; Yuce H; Guo JD
J Thromb Thrombolysis; 2023 Nov; 56(4):626-634. PubMed ID: 37530954
[TBL] [Abstract][Full Text] [Related]
34. Validation of a Modified CHA2DS2-VASc Score for Stroke Risk Stratification in Asian Patients With Atrial Fibrillation: A Nationwide Cohort Study.
Chao TF; Lip GY; Liu CJ; Tuan TC; Chen SJ; Wang KL; Lin YJ; Chang SL; Lo LW; Hu YF; Chen TJ; Chiang CE; Chen SA
Stroke; 2016 Oct; 47(10):2462-9. PubMed ID: 27625386
[TBL] [Abstract][Full Text] [Related]
35. CHA
Carr BW; Wooster ME; Nemani LA; Severance SE; Hartwell JL
Am J Emerg Med; 2022 Jan; 51():119-123. PubMed ID: 34735969
[TBL] [Abstract][Full Text] [Related]
36. Association of Race and Ethnicity With Oral Anticoagulation and Associated Outcomes in Patients With Atrial Fibrillation: Findings From the Get With The Guidelines-Atrial Fibrillation Registry.
Essien UR; Chiswell K; Kaltenbach LA; Wang TY; Fonarow GC; Thomas KL; Turakhia MP; Benjamin EJ; Rodriguez F; Fang MC; Magnani JW; Yancy CW; Piccini JP
JAMA Cardiol; 2022 Dec; 7(12):1207-1217. PubMed ID: 36287545
[TBL] [Abstract][Full Text] [Related]
37. Contemporary clinical and economic outcomes among oral anticoagulant treated and untreated elderly patients with atrial fibrillation: Insights from the United States Medicare database.
Munir MB; Hlavacek P; Keshishian A; Guo JD; Mallampati R; Ferri M; Russ C; Emir B; Cato M; Yuce H; Hsu JC
PLoS One; 2022; 17(2):e0263903. PubMed ID: 35176074
[TBL] [Abstract][Full Text] [Related]
38. The IMPact of untReated nOn-Valvular atrial fibrillation on short-tErm clinical and economic outcomes in the US Medicare population: the IMPROVE-AF model.
Sussman M; Di Fusco M; Tao CY; Guo JD; Gillespie JA; Ferri M; Adair N; Cato MS; Shirkhorshidian I; Barnes GD
J Med Econ; 2021; 24(1):1070-1082. PubMed ID: 34415229
[TBL] [Abstract][Full Text] [Related]
39. Changes in primary care management of atrial fibrillation patients following the shift from warfarin to non-vitamin K antagonist oral anticoagulants: a Norwegian population based study.
Halvorsen S; Smith JA; Söderdahl F; Thuresson M; Solli O; Ulvestad M; Jonasson C
BMC Prim Care; 2022 Aug; 23(1):214. PubMed ID: 36008778
[TBL] [Abstract][Full Text] [Related]
40. Incident Co-Morbidities in Patients with Atrial Fibrillation Initially with a CHA2DS2-VASc Score of 0 (Males) or 1 (Females): Implications for Reassessment of Stroke Risk in Initially 'Low-Risk' Patients.
Chao TF; Liao JN; Tuan TC; Lin YJ; Chang SL; Lo LW; Hu YF; Chung FP; Chen TJ; Lip GYH; Chen SA
Thromb Haemost; 2019 Jul; 119(7):1162-1170. PubMed ID: 30900222
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
